Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38828946

Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2024 Aug 15
First author
Lu S

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    CA Cancer J Clin. 2024 Sep-Oct;74(5):402-404. doi: 10.3322/caac.21862.
    note
    Source null
    related pmid
    39223442
    relationship
    Comment in
  2. citation
    N Engl J Med. 2024 Oct 24;391(16):1555. doi: 10.1056/NEJMc2411471.
    note
    Source null
    related pmid
    39442049
    relationship
    Comment in
  3. citation
    N Engl J Med. 2024 Oct 24;391(16):1555-1556. doi: 10.1056/NEJMc2411471.
    note
    Source null
    related pmid
    39442050
    relationship
    Comment in
  4. citation
    Transl Lung Cancer Res. 2024 Oct 31;13(10):2853-2855. doi: 10.21037/tlcr-24-540.
    note
    Source null
    related pmid
    39507046
    relationship
    Comment in

Authors and identifiers

  1. name
    Lu S
    type
    Author
  2. name
    Kato T
    type
    Author
  3. name
    Dong X
    type
    Author
  4. name
    Ahn MJ
    type
    Author
  5. name
    Quang LV
    type
    Author
  6. name
    Soparattanapaisarn N
    type
    Author
  7. name
    Inoue T
    type
    Author
  8. name
    Wang CL
    type
    Author
  9. name
    Huang M
    type
    Author
  10. name
    Yang JC
    type
    Author
  11. name
    Cobo M
    type
    Author
  12. name
    Özgüroğlu M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Lu S
    type
    Author
  2. name
    Kato T
    type
    Author
  3. name
    Dong X
    type
    Author
  4. name
    Ahn MJ
    type
    Author
  5. name
    Quang LV
    type
    Author
  6. name
    Soparattanapaisarn N
    type
    Author
  7. name
    Inoue T
    type
    Author
  8. name
    Wang CL
    type
    Author
  9. name
    Huang M
    type
    Author
  10. name
    Yang JC
    type
    Author
  11. name
    Cobo M
    type
    Author
  12. name
    Özgüroğlu M
    type
    Author
bibliography ids
  1. nci-bib-777ffbe371ea18b7c68bbdbf
book metadata
content sha256
ff776e299310a69bbbf97d66b64bf3ad446ca723b8fb7112dba056bc890125de
document type
citation
dois
  1. 10.1056/NEJMoa2402614
electronic publication date
display
2024 Jun 2
precision
day
year
2024
evidence scope
bibliographic_metadata_only
id
pubmed:38828946
immutable id
pubmed:38828946@ff776e299310a69bbbf97d66b64bf3ad446ca723b8fb7112dba056bc890125de
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
7
name
The New England journal of medicine
nlm unique id
0255562
pages
585-597
volume
391
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    CA Cancer J Clin. 2024 Sep-Oct;74(5):402-404. doi: 10.3322/caac.21862.
    note
    Source null
    related pmid
    39223442
    relationship
    Comment in
  2. citation
    N Engl J Med. 2024 Oct 24;391(16):1555. doi: 10.1056/NEJMc2411471.
    note
    Source null
    related pmid
    39442049
    relationship
    Comment in
  3. citation
    N Engl J Med. 2024 Oct 24;391(16):1555-1556. doi: 10.1056/NEJMc2411471.
    note
    Source null
    related pmid
    39442050
    relationship
    Comment in
  4. citation
    Transl Lung Cancer Res. 2024 Oct 31;13(10):2853-2855. doi: 10.21037/tlcr-24-540.
    note
    Source null
    related pmid
    39507046
    relationship
    Comment in
outcomes validated
false
pmid
38828946
provenance
batch id
6d213eecf21b6b7867cb
provider
NCBI PubMed ESummary
record sha256
00fe304b9493b4ec8482a618f6b8b32801a880ca93df5b8122c4ebb717aadce5
response sha256
684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
retrieved at
2026-09-09T23:48:19.049083+00:00
publication date
display
2024 Aug 15
precision
day
year
2024
publication types
  1. Journal Article
  2. Randomized Controlled Trial
  3. Clinical Trial, Phase III
  4. Multicenter Study
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/38828946/
title
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.

Preserved source evidence · Not medical advice